Trump Signs Executive Order to Accelerate Psychedelic Research
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 13 hours ago
0mins
Should l Buy CMND?
Source: stocktwits
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CMND?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CMND
About CMND
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clearmind's Drug Clinical Trial Achieves Success
- Clinical Trial Success: Clearmind Medicine Inc.'s CMND-100 drug has met the primary safety and tolerability endpoints in its FDA-approved Phase I/IIa clinical trial, indicating promising prospects for treating Alcohol Use Disorder (AUD).
- Safety Data: Results from the third cohort show that CMND-100 exhibited a high safety profile even at higher doses, with no serious adverse events reported, further validating the drug's tolerability across different dosages.
- Multinational Study: The clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, supporting its potential as a novel non-hallucinogenic treatment option.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families, including 31 granted patents, and plans to continue seeking additional patents to enhance its competitive position in the psychedelic drug market.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
See More
Clearmind Medicine's CMND-100 Trial Receives Positive DSMB Recommendation
- Clinical Trial Progress: Clearmind Medicine Inc.'s independent Data and Safety Monitoring Board has issued a positive recommendation for the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, indicating the drug's potential in treating Alcohol Use Disorder, particularly in light of limited effective treatment options.
- Positive Safety Data: Following the successful completion of the third patient cohort, top-line safety data for CMND-100 shows it was well tolerated with no serious adverse events reported, reinforcing the favorable safety profile observed in earlier cohorts.
- Dose Increase: As the trial advances to the fourth cohort, the tested dose of CMND-100 will increase to 160 mg, aimed at evaluating the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy, demonstrating the company's confidence in its drug development.
- Stock Market Volatility: Despite a 28.57% drop in CMND's stock price to $0.65 during Wednesday's trading, the stock rebounded slightly to $0.66 in overnight trading, reflecting market interest and anticipation regarding the drug trial's progress.
See More
Clearmind's Drug Trial Achieves Primary Endpoint
- Clinical Trial Success: Clearmind Medicine Inc. announced that its CMND-100 drug has met the primary safety and tolerability endpoint in its FDA-approved Phase I/IIa clinical trial, indicating strong potential for treating Alcohol Use Disorder (AUD).
- High Safety Profile: Results from the third cohort demonstrated that CMND-100 exhibited a high safety profile even at higher dosages, with no serious adverse events reported, further confirming the drug's tolerability consistent with previous cohorts.
- Multinational Study Design: The clinical trial is a multinational, multicenter study aimed at evaluating the safety, tolerability, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, supporting its potential as a novel non-hallucinogenic treatment option.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, enhancing its competitive position in the neuroplastogen-derived therapeutics market.
See More
Clearmind Medicine Reports Positive Progress in AUD Drug Trial
- Clinical Trial Progress: Clearmind Medicine Inc. has successfully completed treatment and follow-up for 18 participants in its Phase 1/2a clinical trial for CMND-100, a non-hallucinogenic drug for Alcohol Use Disorder (AUD), reflecting strong momentum across its multinational study sites.
- Patient Recruitment Expansion: The successful treatment of four additional participants at the Tel Aviv clinical site further expands enrollment, demonstrating the operational strength of its Israeli centers while providing more data to support the drug's potential efficacy.
- Urgent Treatment Need: AUD is a chronic condition with limited existing treatments, making the development of CMND-100 significant as it may offer new therapeutic options for patients struggling with long-term recovery.
- Safety and Tolerability: CEO Dr. Adi Zuloff-Shani noted that the steady progress underscores the favorable safety and tolerability profile of CMND-100, bringing the company closer to delivering an innovative therapy for AUD and advancing its pipeline of non-hallucinogenic therapeutics.
See More
Clearmind Advances Clinical Trial for Alcohol Use Disorder
- Clinical Trial Progress: Clearmind Medicine has successfully completed treatment and follow-up for 18 participants in its FDA-approved Phase I/IIa clinical trial, indicating a favorable safety and tolerability profile for its non-hallucinogenic drug CMND-100 aimed at treating Alcohol Use Disorder, thereby enhancing the company's innovative capabilities in the biotech sector.
- Israeli Center Expansion: The successful treatment of four additional participants at the Tel Aviv clinical center demonstrates the operational strength of this site, increasing Clearmind's engagement in the multicenter study and potentially accelerating the recruitment of subsequent patients.
- Multicenter Research Advantage: Conducted at leading institutions such as Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, the trial ensures scientific rigor and enhances Clearmind's reputation within the industry, positioning it favorably for future collaborations.
- Intellectual Property Strategy: Clearmind's portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, reflecting its long-term strategic positioning and competitive edge in the drug development landscape.
See More
Clearmind's Drug Clinical Trial Achieves Success
- Clinical Trial Success: Clearmind Medicine Inc.'s CMND-100 drug has met the primary safety and tolerability endpoints in its FDA-approved Phase I/IIa clinical trial, indicating promising prospects for treating Alcohol Use Disorder (AUD).
- Safety Data: Results from the third cohort show that CMND-100 exhibited a high safety profile even at higher doses, with no serious adverse events reported, further validating the drug's tolerability across different dosages.
- Multinational Study: The clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, supporting its potential as a novel non-hallucinogenic treatment option.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families, including 31 granted patents, and plans to continue seeking additional patents to enhance its competitive position in the psychedelic drug market.
See More
Trump Signs Executive Order to Accelerate Psychedelic Research
- Funding Support: Trump signed an executive order allocating $50 million for psychedelic research aimed at accelerating studies on PTSD treatments, potentially paving the way for future drug reclassification.
- Clearmind Drug Progress: Clearmind Medicines' CMND-100 met its primary goal in early-stage trials, demonstrating strong safety with no serious side effects reported at higher doses, likely enhancing its market competitiveness.
- Market Reaction: Clearmind's shares surged nearly 65% in pre-market trading, marking its largest intraday gain since August 2022, reflecting strong investor interest in the therapeutic potential of psychedelics.
- Silo Pharma Development: Silo Pharma is developing SPC-15, a nasal spray designed to prevent PTSD, utilizing a fast nose-to-brain delivery method, and is expected to benefit from a more favorable regulatory environment.
See More
Clearmind Medicine's CMND-100 Trial Receives Positive DSMB Recommendation
- Clinical Trial Progress: Clearmind Medicine Inc.'s independent Data and Safety Monitoring Board has issued a positive recommendation for the ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, indicating the drug's potential in treating Alcohol Use Disorder, particularly in light of limited effective treatment options.
- Positive Safety Data: Following the successful completion of the third patient cohort, top-line safety data for CMND-100 shows it was well tolerated with no serious adverse events reported, reinforcing the favorable safety profile observed in earlier cohorts.
- Dose Increase: As the trial advances to the fourth cohort, the tested dose of CMND-100 will increase to 160 mg, aimed at evaluating the drug's safety, tolerability, pharmacokinetics, and preliminary efficacy, demonstrating the company's confidence in its drug development.
- Stock Market Volatility: Despite a 28.57% drop in CMND's stock price to $0.65 during Wednesday's trading, the stock rebounded slightly to $0.66 in overnight trading, reflecting market interest and anticipation regarding the drug trial's progress.
See More
Clearmind's Drug Trial Achieves Primary Endpoint
- Clinical Trial Success: Clearmind Medicine Inc. announced that its CMND-100 drug has met the primary safety and tolerability endpoint in its FDA-approved Phase I/IIa clinical trial, indicating strong potential for treating Alcohol Use Disorder (AUD).
- High Safety Profile: Results from the third cohort demonstrated that CMND-100 exhibited a high safety profile even at higher dosages, with no serious adverse events reported, further confirming the drug's tolerability consistent with previous cohorts.
- Multinational Study Design: The clinical trial is a multinational, multicenter study aimed at evaluating the safety, tolerability, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, supporting its potential as a novel non-hallucinogenic treatment option.
- Intellectual Property Strategy: Clearmind currently holds 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, enhancing its competitive position in the neuroplastogen-derived therapeutics market.
See More
Clearmind Medicine Reports Positive Progress in AUD Drug Trial
- Clinical Trial Progress: Clearmind Medicine Inc. has successfully completed treatment and follow-up for 18 participants in its Phase 1/2a clinical trial for CMND-100, a non-hallucinogenic drug for Alcohol Use Disorder (AUD), reflecting strong momentum across its multinational study sites.
- Patient Recruitment Expansion: The successful treatment of four additional participants at the Tel Aviv clinical site further expands enrollment, demonstrating the operational strength of its Israeli centers while providing more data to support the drug's potential efficacy.
- Urgent Treatment Need: AUD is a chronic condition with limited existing treatments, making the development of CMND-100 significant as it may offer new therapeutic options for patients struggling with long-term recovery.
- Safety and Tolerability: CEO Dr. Adi Zuloff-Shani noted that the steady progress underscores the favorable safety and tolerability profile of CMND-100, bringing the company closer to delivering an innovative therapy for AUD and advancing its pipeline of non-hallucinogenic therapeutics.
See More
Clearmind Advances Clinical Trial for Alcohol Use Disorder
- Clinical Trial Progress: Clearmind Medicine has successfully completed treatment and follow-up for 18 participants in its FDA-approved Phase I/IIa clinical trial, indicating a favorable safety and tolerability profile for its non-hallucinogenic drug CMND-100 aimed at treating Alcohol Use Disorder, thereby enhancing the company's innovative capabilities in the biotech sector.
- Israeli Center Expansion: The successful treatment of four additional participants at the Tel Aviv clinical center demonstrates the operational strength of this site, increasing Clearmind's engagement in the multicenter study and potentially accelerating the recruitment of subsequent patients.
- Multicenter Research Advantage: Conducted at leading institutions such as Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, the trial ensures scientific rigor and enhances Clearmind's reputation within the industry, positioning it favorably for future collaborations.
- Intellectual Property Strategy: Clearmind's portfolio includes 19 patent families and 31 granted patents, with plans to seek additional patents as warranted, reflecting its long-term strategic positioning and competitive edge in the drug development landscape.
See More
